Bristol Myers Squibb Company $BMY Shares Bought by OLD National Bancorp IN

OLD National Bancorp IN raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 8.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 220,603 shares of the biopharmaceutical company’s stock after purchasing an additional 16,575 shares during the period. OLD National Bancorp IN’s holdings in Bristol Myers Squibb were worth $9,949,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb in the second quarter worth about $25,000. Trifecta Capital Advisors LLC purchased a new position in shares of Bristol Myers Squibb in the second quarter worth $25,000. REAP Financial Group LLC raised its stake in Bristol Myers Squibb by 202.8% in the 2nd quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 428 shares during the last quarter. CBIZ Investment Advisory Services LLC raised its stake in shares of Bristol Myers Squibb by 66.0% in the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 231 shares during the last quarter. Finally, DHJJ Financial Advisors Ltd. increased its holdings in Bristol Myers Squibb by 51.9% in the 2nd quarter. DHJJ Financial Advisors Ltd. now owns 781 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 267 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 0.9%

BMY opened at $54.68 on Tuesday. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. The company’s 50 day simple moving average is $47.95 and its two-hundred day simple moving average is $47.18. The firm has a market capitalization of $111.32 billion, a price-to-earnings ratio of 18.47, a price-to-earnings-growth ratio of 8.29 and a beta of 0.29. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, topping analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The company had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. During the same quarter in the previous year, the company posted $1.80 earnings per share. The firm’s revenue for the quarter was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be given a $0.63 dividend. The ex-dividend date of this dividend is Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a yield of 4.6%. Bristol Myers Squibb’s dividend payout ratio is presently 83.78%.

Analysts Set New Price Targets

Several analysts have commented on the stock. Truist Financial set a $65.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, December 3rd. Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Morgan Stanley restated an “underweight” rating and set a $37.00 target price (up from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Bank of America raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their target price for the stock from $52.00 to $61.00 in a research note on Monday, December 15th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. Five equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $54.62.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.